PL EN
Bipolar disorder in children, adolescents and young adults. Part 2. Therapeutic management. Recommendations under the patronage of the Executive Board of the Polish Psychiatric Association, National Consultants in the field of Psychiatry and National Consultants in Child and Adolescent Psychiatry
 
More details
Hide details
1
Specjalistyczny Psychiatryczny Zespół Opieki Zdrowotnej im. J. Babińskiego w Łodzi, Oddział Psychiatryczny dla Dzieci
 
2
Śląski Uniwersytet Medyczny w Katowicach, Katedra i Oddział Kliniczny Psychiatrii i Psychoterapii Wieku Rozwojowego
 
3
Centrum Zdrowia Dziecka i Rodziny im. Jana Pawła II w Sosnowcu Sp.z o.o.
 
4
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Klinika Psychiatrii Dzieci i Młodzieży
 
5
Uniwersytet Jagielloński Collegium Medicum, Katedra Psychiatrii, Klinika Psychiatrii Dorosłych
 
6
Uniwersytet Medyczny w Łodzi, Klinika Psychiatrii Dorosłych
 
7
Instytut Psychiatrii i Neurologii, Klinika Psychiatrii Dzieci i Młodzieży
 
 
Submission date: 2024-05-19
 
 
Final revision date: 2024-07-19
 
 
Acceptance date: 2024-09-14
 
 
Online publication date: 2025-06-30
 
 
Publication date: 2025-06-30
 
 
Corresponding author
Barbara Remberk   

Instytut Psychiatrii i Neurologii
 
 
Psychiatr Pol 2025;59(3):359-372
 
KEYWORDS
TOPICS
ABSTRACT
Bipolar disorder is characterized by recurrent episodes of depression, mania, hypomania, or mixed states. Early diagnosis and comprehensive treatment, including pharmacotherapy and psychosocial interactions, are associated with a more favorable prognosis. The general principles for the use of drugs in bipolar disorder in children and adolescents remain similar to those in adults. The basic drugs in bipolar disorder are mood stabilizers of the first and second generation; however, their efficacy and safety profile in children and adolescents differ from those in adults. In addition, prophylactic treatment is necessary to prevent recurrence. Lithium, aripiprazole, quetiapine, risperidone, olanzapine, asenapine, ziprasidone are recommended for the treatment of mania and mixed states. For the treatment of depressive episodes in bipolar disorder in children and adolescents, experts recommend lurasidone as monotherapy or olanzapine + fluoxetine as combination therapy. Although long-term treatment is a key aspect of bipolar disorder management in children and adolescents, consistent efficacy data are still lacking. Safety data indicate that the most commonly reported adverse reactions in children and adolescents treated with mood stabilizers are gastrointestinal and neurological adverse reactions, while the use of antipsychotics is mainly associated with weight gain and sedation.
eISSN:2391-5854
ISSN:0033-2674
Journals System - logo
Scroll to top